HealthCapital Newsletter August 2021
HealthCapital Newsletter August 2021 If this newsletter is not displayed properly, please click here. Land Brandenburg und be Berlin
load images
HealthCapital Newsletter August 2021

Dear Sir or Madam,

Rarely have medical issues been so high on the agenda and never before have life science companies from Berlin been so attractive to investors worldwide. In recent weeks, the companies Ada Health, Caresyntax and T-knife alone have been able to secure financing from international investors of USD 300 million. They focus on digital health, artificial intelligence and innovative therapies. In this edition’s interview, Björn von Siemens, co-founder of Caresyntax, will explain the role of data analysis and artificial intelligence in the operating theatre and why such developments are being driven from Berlin.

We’re already looking forward to exciting interaction in Autumn. Our virtual event “Liquid Biopsy and beyond - less invasion, more precision” (14 September 2021) will present approaches for artificial intelligence in diagnostics, among other things.

We warmly invite you to discuss this and many other topics with us. We will be once again at BIO-Europe digitally (25-28 October 2021) and of course the World Health Summit (24-26 October 2021 in Berlin) offers great opportunities for discussion and collaboration. The challenges of global healthcare systems in the light of the pandemic will be an important topic at WHS and the development of artificial intelligence systems for healthcare.

We look forward to seeing you!

Dr. Kai Uwe Bindseil
Clustermanager HealthCapital Berlin-Brandenburg





    Björn von Siemens is co-founder and managing director of caresyntax GmbH. The company develops algorithms that analyse risk factors during surgery and provide decision support. The company, based in Berlin and Boston, recently raised 100 million US dollars in a Series C financing round. In an interview, the direct descendant of Werner von Siemens talks about how the money will be employed, amongst other things.




    3 September 2021

    Startup Academy: Founding a GmbH

    » mehr
    14 September 2021

    Technology Forum “Liquid Biopsy and beyond - less invasion, more precision”

    » mehr
    24 – 26 October 2021

    World Health Summit

    » mehr
    25 – 28 October 2021


    » mehr

    For more events in the life science region Berlin-Brandenburg click here.



    T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

    T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with participation from other new investors including, LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners. The company plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T).


    Get more background information on T-Knife


    Asher Biotherapeutics contracts ProBioGen to develop and manufacture their Lead Candidate

    ProBioGen AG today announced that Asher Biotherapeutics, Inc., has entered into a service agreement covering all aspects of cell line development, process development and GMP manufacturing at 1000 L bioreactor scale.
    ProBioGen will now advance the development of Asher's lead candidate in immuno-oncology applying its unique transposase technology DirectedLuckTM which greatly accelerates time-to-clinic.



    Leaps by Bayer leads USD 90 Million Series B financing in digital health company Ada Health 

    Leaps by Bayer, the impact investment arm of Bayer AG, today announces that it has led a USD 90 million Series B investment in Berlin-based digital health company Ada Health GmbH (“Ada”). Additional investors joined the round, including Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures.



    Delivery Hero-backed DX Ventures invests in Bluu Biosciences to pave the way for cell-based fish in Europe’s kitchens 

    » more

    Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders 

    » more

    RDIF and Minapharm agree to produce over 40 Million doses of the Sputnik V vaccine in Egypt

    » more

    Interview with Dr. Felix Lorenz, founder of the Berlin-based Captain T-Cell start-up project, on cancer therapy for patients

    » more

    Science and Technology News 


    WHO and Germany launch new global hub for pandemic and epidemic intelligence in Berlin 

    The World Health Organization (WHO) and the Federal Republic of Germany will establish a new global hub for pandemic and epidemic intelligence, data, surveillance and analytics innovation. The Hub, based in Berlin and working with partners around the world, will lead innovations in data analytics across the largest network of global data to predict, prevent, detect prepare for and respond to pandemic and epidemic risks worldwide. 



    Charité team determined the viral loads in SARS-CoV-2 patiens to estimate levels of infectiousness 

    What started as the preliminary analysis of routine laboratory data has since evolved into the largest-ever study of viral load levels in patients with SARS-CoV-2. A team of researchers from Charité – Universitätsmedizin Berlin have now analyzed the PCR samples of more than 25,000 persons with COVID-19. Working under the leadership of Prof. Dr. Christian Drosten, the team determined the viral loads of each individual sample and used their results to estimate levels of infectiousness. The research, which has been published in Science*, provides a clear idea of the infectiousness of the disease in different age groups and at different levels of disease severity. It also provides new insights into the B.1.1.7 variant.



    CRP blood wash therapy: Promising treatment success in patients with severe COVID-19 courses 

    Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.



    Einstein Center 3R aims to advance animal-free research 

    » more

    New gene-editing technique is paving the way for the first potential cell therapy for genetic muscle disorders 

    » more

    Enzymes successfully embedded in plastics

    » more

    Charité study confirms delayed immune response in the elderly 

    » more

    MDC has succeeded in tracking genes through space and time within a one-cell zebrafish embryo 

    » more

    Charité and MDC have discovered a sugar molecule whose levels are reduced in the blood of patients with particularly severe multiple sclerosis. 

    » more

    Researchers from Charite show relation of gut bacterium and weight control 

    » more

    For more news from the cluster healthcare industries click here.



    Technology and Cooperation Offers  


    Chip-integrated optical sensor offered under license or research agreement 

    » more

    Novel Self-Organizing 3D Human Neuromuscular Organoids 

    » more


    The operator and party responsible for content in compliance with § 5 of the German Teleservices Act (TaMG) and in the meaning of the German Press Act:

    Berlin Partner for Business and Technology GmbH
    Fasanenstraße 85 | 10623 Berlin, Germany
    Telephone: +49 30 46302-270
    E-Mail: info (at)

    Commercial Registry Entry
    Entered in the commercial registry of the Charlottenburg District Court,
    Registration number: HRB 13072 B
    VAT ID: DE 136629780

    Dr. Stefan Franzke

    Acting Executive Chairwoman:
    Senator Ramona Pop

    V. i. S. d. P. Lukas Breitenbach, Head of Corporate Communications Berlin Partner für Wirtschaft und Technologie GmbH
    © 2021 Berlin Partner für Wirtschaft und Technologie GmbH

    Unsubscribe from the newsletter
    The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology. Funded by the federal state of Berlin and the European Regional Development fund through the Investitionsbank Berlin.

    load images load images
    load images